Vaishnavi Group Offers Residential Plotted Development With Its Latest Offering ‘Vaishnavi Life’

Vaishnavi Group, a renowned Bengaluru real estate developer with an enviable track record of over 23 years of ahead of schedule delivery, has announced the launch of  ‘Vaishnavi Life’,  a premium plotted development located at Yelahanka Extension,  just 25 minutes from Hebbal flyover.

Spread across 45+ acres, Vaishnavi Life features pre-engineered and smart plots ranging from 1150 – 3550 sq. ft. Vaishnavi Life boasts of a host of thoughtfully planned amenities such as a courtyard-themed 32,750 sq.ft clubhouse, 14 thematic parks and over two acres of central activity space amongst others.  

Commenting on the launch of the premium plotted development project, Mr. C N Govindaraju, Chairman & Managing Director, Vaishnavi Group said, “Vaishnavi Life is an outcome of a larger vision to deliver premium residential plots and thoughtful, yet luxurious amenities for discerning home buyers in Bengaluru. The company has garnered customer goodwill for delivering projects ahead of schedule.  Now, through Vaishnavi Life, we at Vaishnavi are redefining the concept of premium plotted developments.”

“Currently, we see that North Bengaluru is the most preferred among seasoned investors as well as first time home buyers as a viable option for long-term real estate investment. Connectivity to the arterial Outer Ring Road as well as proximity to the Kempegowda International Airport apart from access to Bangalore’s CBD are the key factors driving this demand,” he added.

Yelahanka, touted as a high growth location is also peaceful and safe owing to the multiple defence establishments. Located before the airport toll, Vaishnavi Life, is strategically located with access to all parts of Bangalore as well as the peaceful environs of Yelahanka extension.

The residential plots at Vaishnavi Life start from Rs. 49.10 lakh onwards.  

For more details, contact + Priya and contact no 91-9900962760 email id: priya@vaishnavigroup.com

About Vaishnavi Group

Vaishnavi Group, a Bangalore based real estate company was started with the explicit aim of making a mark in the real estate segment as the most admired brand for its integrity, commitment and for exceeding expectations consistently. Started in 1998 by its charismatic leader, C N Govindaraju, a civil engineer by profession, the Group has come a long way, carving a niche for creating boutique projects, leaving an indelible mark amidst its expanding customer base. Never inclined to be a volume player, Vaishnavi Group has always been focused on smart developments that ensures micro focus and stringent quality control.

For more information log on to:  www.vaishnavilife.com

Over 80% Newly Diagnosed Diabetic Patients In India Have At Least One Cholesterol Abnormality: India Diabetes Study Reveals

 * Lipid abnormalities were determined basis the mentioned cut-offs recommended by LAI (Lipid Association of India): HDL (High-density lipoprotein) < 40 mg/dL for males HDL<50 mg/dL for females, LDL (Low-density lipoprotein) ?130 mg/dL, total cholesterol ?200 mg/dL, TG (Triglycerides) ?150 m/dL

* The findings of this first-of-its-kind study support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted

India Diabetes Study (I.D.S.) revealed that over 55% of newly diagnosed1 Type 2 Diabetes Mellitus (T2DM) patients in India have low HDL-C (High Density Lipid – Cholesterol) values, indicating that they are at higher risk of developing some form of cardiovascular disease in their lifetime. The study also suggested that 42% of all T2DM patients are at a high risk of hypertension. Mean BMI of the patients was recorded to be 27.2 – classified as overweight as per the Indian Consensus Group guidelines.

The one-of-its-kind nation-wide study supported by Eris Lifesciences and co-authored by 16 doctors between 2020- 2021, was conducted in partnership with over 1900 physicians and had a sample size of 5080 patients with mean age of 48 years, from across 27 states in India. It has been published in the Public Library of Science (PLOS) journal.

Following the recent recommendations from the LAI and QRISK3 score2, the study aimed at investigating the extent of cardiovascular disease (CVD) risk in newly diagnosed T2DM patients in India. It also highlighted some ways to manage dyslipidaemia – high cholesterol (fats) – in newly diagnosed Type 2 diabetes patients.

Other key findings from this study, with respect to newly diagnosed type 2 diabetes mellitus patients include:

92.5% and 83.5% of the total patients are not on any cholesterol lowering and anti-hypertension treatment

Low HDL-C value was the most frequent major risk (55.6%)

82.5% patients appeared to have at least one cholesterol abnormality

37.3% patients were hypertensive and younger than 65 years of age

According to the QRISK3 calculation the obese patients in the current population had 17.1% risk of CVD as compared to 14.8% for those with lower BMI

11.2% patients had Target Organ Damage – a chronic kidney disease in the 3b or higher stage

Dr A. G. Unnikrishnan, CEO and Chief of Endocrinology at Chellaram Diabetes Institute, Pune, and the Principal Investigator of IDS, said, “India Diabetes Study focused on highlighting the cardiovascular risk factors in newly diagnosed diabetes patients across India. While treatment should focus on dietary changes, physical activity and glucose control, additionally addressing cardiovascular risk by strategies like blood pressure control and lipid  management offer a more holistic way of management– as also suggested in the India Diabetes Study.”

Dr R. K. Sahay, Department of Endocrinology, Osmania Medical College, Osmania General Hospital, Hyderabad, President of Endocrinology Society of India and the co-author of the study said, “Atherosclerotic cardiovascular disease is a significant risk factor in diabetic patients. Along with glucose control, it is important to follow a robust regimen that is inclusive of optimum lipid lowering treatment, in order to reduce CVD risk. Another important finding that emerged from the study is the increased average BMI (Body Mass Index) of Indians. Physical activity and diet control are crucial to managing diabetes effectively. ”

Mr Manish Kapoor, Vice President at Eris Lifesciences said, “Eris has been at the forefront of generating actionable medical evidence through India-centric studies on chronic ailments. On the back of the India Heart Study conducted in the year 2019, the India Diabetes Study marks another step in this direction. This study was designed to understand the CVD risk factors observed in a population of newly-diagnosed T2DM patients in India. We strongly believe that these insights will guide medical experts in the diagnosis and management of type 2 diabetes in India.”

IIIT Bangalore Begins Admissions For The Academic Year 2022-23

The International Institute of Information Technology Bangalore (IIIT-B), one of the premier institutes focused on Post-Graduate IT education and research has begun the admission process for M.Tech Computer Science and Engineering (CSE), M.Tech. in Electronics and Communication Engineering (ECE), Master of Science in Digital Society (MSc DT), Master of Science By Research (MS by Research) and Doctor of Philosophy (PhD) programmes. 

Programmes, Eligibility, Criteria & Last date for applications

1.M.Tech (CSE&ECE)

Eligibility Criteria: 65% in four-year bachelor's degree in engineering (i.e. B.E., B.Tech., or equivalent)

Last Date for Applications: May 9, 2022

2.MSc Digital Society

Eligibility Criteria : Undergraduate degree (of at least 3 years duration) in any discipline (including arts, science, commerce, design, management, law, engineering, etc.) with a first division/class from a recognized University.

Last Date for Applications - May 15, 2022

3. MS by Research

Eligibility Criteria :B.E, B. Tech or equivalent

Last Date for Applications: April 18, 2022

4.PhD

Eligibility Criteria- Master’s Degree( M. Sc maths or computer science,ME, M. Tech(computer science)

Last Date for Applications:April 18, 2022

Click here for more details about the programmes and admissions:https://www.iiitb.ac.in/admissions

For any urgent technical issues on the applicant portal, please reach out via Whatsapp at the number +91-9770502091.

About IIIT Bangalore

IIIT Bangalore is a premier institute focused on Post-Graduate IT education and research, located in the heart of Electronic City, Bangalore. IIIT Bangalore is graded A+ by National Assessment and Accreditation Council (NAAC) and remains top 70 in the National Institutional Ranking Framework since the last four years. The institute was ranked number 1 among India's Best Technical Universities (Private) by India Today. IIIT Bangalore contains state-of-the-art infrastructure, world-class faculty, a vibrant alumni community, cutting-edge research facilities and close industry collaborations. 

The institute’s specially designed courses make the students cognitive of the current technologies and practices, thereby equipping them with the tools and knowledge to solve contemporary real problems. Since the founding of the Institute in 1998, IIIT Bangalore has enjoyed 100% placement every year, on account of the strong support of the industry and the growing base of talented alumni.

https://www.iiitb.ac.in/

PrepLAdder To Provide Guidance To UPSC Aspirants With Free Access To Study Material

* Renders 7 Days Free Access Of The App To Students Preparing For The Upcoming UPSC Exams

PrepLadder, a leading online learning platform, eases the hardships of UPSC aspirants, with free access to all its premium UPSC study material for a period of 7 days. The intent is to ease the lives of these students and help budding UPSC civil service aspirants pursue their dream.

The brand understands the importance of guidance in decoding the preparation strategy. With its expert faculty like Hemant Jha, M Puri, Himanshu Sharma, Vivek Singh & Pavneet Singh among other leading professors in India, the platform is set to help the budding civil service aspirants pursue their career goals.

Deepanshu Goyal, Co-Founder, and CEO, PrepLadder said, “The aim is to make coaching and guidance available to all and the idea behind this is to help more students and be a small part of their journey to success. We believe this initiative will help students to connect with us and get access free to the top class faculties and study material.”

Almost a decade old, PrepLadder is a brainchild of young entrepreneur Deepanshu Goyal the Co-Founder and CEO of PrepLadder. His vision is to ensure the company’s long-term viability, and ensure that every student is facilitated to reach their full potential.

The aspirants can sign up on the PrepLadder app and unlock the entire application by using the code FREETRIAL.

About PrepLadder

PrepLadder has succeeded in making quality education accessible to Medical, Engineering, Civil Services, and Management students, on their preferred devices. They are now expanding into additional domains such as CAT, UPSC, and GATE. The company aspires to be a guiding pillar in a student's journey to crack their dream exam by providing top-notch content, engaging HD video lectures, study materials, high-yield question banks, test series, patterned prep tests, comprehensive notes, access to treasures, customs modules, and detailed performance analysis.

Over 2 million downloads, with over 1 million doubts cleared and over 3 million tests completed so far, PrepLadder’s mission is to create a world where no aspiring student regrets choosing to study on the platform, and to provide access to the best guidance with personalized attention for improved results.

Watch What The Cast of Runway 34 Has To Say About Their Director Ajay Devgn In This IMDb Exclusive Video

In an IMDb exclusive video, the cast of Runway 34 share their experience working on the film with Ajay Devgn as he juggles between being an actor and a director in the movie. The supporting roles played by Rakul Preet Singh and Amitabh Bachchan are in awe of his working style.

Amitabh Bachchan was amused by his skills and talks about how the entire experience of shooting with Ajay Devgn as a director was so unique. He also mentioned how during one of their shots, there were multiple cameras placed at different angles and Ajay Devgn would check every camera after the shot to ensure it was captured perfectly. 

The other co-star, Rakul Preet Singh who has worked with Ajay Devgn in the past was surprised looking at the other side of the actor. She was amazed at how he was able to multitask between acting and directing while keeping a steady flow of thought. She added, “So Ajay sir would set up the entire shot and then he is in his casual set up…then he would immediately get into his uniform, and then action, and he would shoot, and then say ‘dikhao’. So, I was like how do you compartmentalise? How do you cut in and out?”

Ajay Devgn shared some insights on how he started the preparations for the movie, laid the groundwork during the pandemic and was able to hit the ground as soon as the lockdown ended in December. All the actors on set shared the same enthusiasm and to quote Amitabh Bachchan, he said, “I applaud him and want to congratulate him on how he has performed perfectly in all his tasks and the audience will see the results of this work in Runway 34”. 

Here is what Ajay Devgn has to say about his journey as he steps in the shoes of a director for Runway 34 - https://m.imdb.com/videoplayer/vi1706672665

Lam Research Earns Intel’s 2022 EPIC Outstanding Supplier Award With Supplier Diversity Distinction

* Lam Research is one of only six Outstanding Award recipients in all of Intel’s global supply chain

Lam Research is proud to announce that it has earned the exclusive EPIC Program Outstanding Supplier Award for 2022. This award recognizes the absolute top performers in the Intel supply chain for their dedication to continuous quality improvement, performance, partnership, and inclusion over the past year.

“Congratulations to Lam Research on receiving Intel’s highest supplier recognition, the EPIC Outstanding Supplier Award. As one of only six companies recognized in 2022, they truly exemplify world-class performance,” said Keyvan Esfarjani, EVP and Global Chief Operations Officer at Intel. “In a truly unique and volatile supply chain environment, Lam Research has earned Intel’s top supplier award through its steadfast commitment to safety, quality, diversity & inclusion, continuous innovation, and its close partnership with Intel toward operational excellence results.”

The Intel EPIC Outstanding Supplier Award recognizes the highest level of achievement in the Intel global supply chain and is an ongoing realization of continuous improvement within the high-performing Intel supplier ecosystem. Of the thousands of Intel suppliers around the world, only a few hundred qualify to participate in the EPIC Supplier Program. In 2022, only six suppliers across the Intel supply chain earned an Intel Outstanding Supplier Award, making them truly the best of the best.

To qualify for an Intel EPIC Outstanding Supplier Award, suppliers must exceed the highest expectations, meet aggressive performance goals, and score 95 percent or higher on performance assessments throughout the year. Suppliers must also meet 90 percent or more of their improvement plan deliverables and demonstrate formidable quality and business systems.

‘Policy transformations Can Catalyze Public And Private Sector Participation To Support MedTech Companies In India

Deep diving into the role that small and medium enterprises(SMEs) can play in advancing the Indian MedTech industry, Wadhwani Foundation, Cyient, and Xynteo’s Vikaasa  partnership published its latest report titled “Accelerating Innovation and scale-up of SMEs in MedTech”. The report highlights two separate strands of analysis: firstly, understanding the challenges and opportunities; secondly, a proposal for recommendations and the way forward to accelerate the adoption of MedTech innovations in public health.

In September 2021, Wadhwani Foundation, Cyient, and Xynteo’s Vikaasa announced a partnership to support and accelerate the growth of Small and Medium Enterprises (SMEs) in the healthcare sector. Marking a step in the right direction, the position paper aims to capture SMEs' need for collaborative platforms and policy transformations to enhance the domestic manufacturing of medical devices and reduce import dependence.

Commenting on the report, Samir Sathe, EVP, Wadhwani Advantage said “Wadhwani Foundation is excited to partner with Xynteo’s Vikaasa and Cyient to provide a pathway to create an evolved domestic medical devices industry. With the right support from Government, both at the Central and State level, Healthcare SMEs can leverage the Atmanirbhar campaign to become the leader in the MedTech space by leveraging technology and developing a collaborative mindset.”   

The paper brings to the fore impact of unclear regulations as one of the biggest impediments to the success of the Medtech industry in India as well as identifies critical gaps as articulated by varied stakeholders around regulations and standards, expanding scale, and adoption of innovations and talent development. Interestingly, the study revealed that only 37 types of medical equipment are regulated in India. At the same time, the market remains flooded with low-cost imports with very high trading margins and long credit periods. Impacting the Indian market, thus reducing the competitiveness of Indian medical devices companies and increasing instances of counterfeit.

Krishna Bodanapu, Managing Director & CEO at Cyient, said, “With its skilled workforce, innovative mindset, and real-world experience, India is poised to become a global player in MedTech. SMEs are future growth engines and are large contributors to employment generation. Supporting the SMEs and enabling them with a go-to-market strategy will enhance the nation’s economic prospects. We are proud to be a partner and look forward to enhanced collaboration with multiple stakeholders enabling India to become a MedTech hub for the world.”

Today, Medtech SMEs account for 60-70 percent of the Indian medical device industry, with an estimated 750-800 MedTech SMEs actively operating in this field. To become a $5 Trillion economy by 2024-25, the study highlights the critical roles of the Central and State governments in building a collaborative mindset across the industry. The paper suggests some policy recommendations including a scheme for the creation of medical devices park, production-linked incentives plans for medical technology and diagnostics, a regulatory roadmap for bringing in all medical devices under the ambit of regulation as well as industry-agnostic support measures for small and medium enterprises to support the growth of the medical devices industry.

The paper highlights the need for Indian medical technology companies to generate enough clinical evidence about their products coupled with peer-reviewed journals, in absence of which, hospitals are unlikely to procure the same for use in their facilities. Indian companies need to invest more in the training of their employees – in sales, marketing, demonstrations, clinical support, hardware repairs, software troubleshooting, regulatory pathways, etc. Initiatives like the International Biomedical Skills Consortium help Indian companies enhance the skills of their employees coupled with Government support through the Health Sector Skills Development Council which can help Indian companies enhance the skills of their employees.

Additionally, there is a need to support market access and scale-up in the form of concessions/ preferential uptake for innovative products and solutions of Indian MedTech companies during procurement, promote mandate digitizing hospital infrastructure and systems so that data from public hospitals can be made available to stakeholders and strengthen infrastructure. 

Vipul Kumar, Director, Xynteo’s Vikaasa, said, “As MedTech companies look to the future, they must now fundamentally reimagine their systems, patient journeys, interfaces, and relationships with healthcare providers. This report is a step forward in establishing that with partnerships geared toward speed and efficiency, a systems change approach, and scaling innovations to deliver meaningful changes, the Medtech SMEs can accomplish India's vision of an Atma Nirbhar Bharat.”

To develop the most promising and impactful deployments for the last mile, the industry will have to build new growth models that focus on partnerships between companies, governments, and researchers and transform regulatory paths and policy support to boost the MedTech industry's growth in India.